来那度胺治疗多发性骨髓瘤患者静脉血栓预防策略比较(4)
Larocca A， Cavallo F， Bringhen S， et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood， 2012， 119(4)： 933-939； quiz 1093.
Palumbo A， Hajek R， Delforge M， et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med， 2012， 366(19)： 1759-1769.
Stewart AK， Jacobus S， Fonseca R， et al. Melphalan， prednisone， and thalidomide vs melphalan， prednisone， and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood， 2015， 126(11)： 1294-1301.
, 百拇医药
Srkalovic G， Cameron M， Rybicki L， et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer， 2004， 101(3)： 558-566.
Rajkumar S， Blood E， Vesole D， et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma： a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol.， 2006， 24(3)： 431-436.
, 百拇医药
Leleu X， Rodon P， Hulin C， et al. MELISSE， a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thromb. Haemost.， 2013， 110(4)： 844-851.
Carrier MLG， G.Tay， J.Wu， C.Lee， A. Y. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide： a systematic review and meta-analysis. J Thromb Haemost， 2011， 9(4)： 653-663.
, http://www.100md.com
Dede RJ， Pruemer JM. Comparing venous thromboembolism prophylactic strategies for ambulatory multiple myeloma patients on immunomodulatory drug therapy. Journal of Oncology Pharmacy Practice， 2016， 22(2)： 248-255.
Louzada MLM， M. V.Siqueira， L.Bermejo， J. M. B.Ocio， E. M.Porras， J. R. Comparing the efficacy of aspirin or low molecular weight heparin or vitamin k antagonists in the risk of thromboembolic events in patients with multiple myeloma treated with lenalidomide-based therapy. Blood， 2015， 126(23)： 1121.
, 百拇医药
Weber D， Chen C， Niesvizky R， et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med.， 2007， 357(21)： 2133-2142.
Rajkumar S， Jacobus S， Callander N， et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma： an open-label randomised controlled trial. Lancet Oncol.， 2010， 11(1)： 29-37., 百拇医药(晏建国 郭瑛 朱文凤 罗萍 胡飞 李金凤 欧阳贤凤)
Palumbo A， Hajek R， Delforge M， et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med， 2012， 366(19)： 1759-1769.
Stewart AK， Jacobus S， Fonseca R， et al. Melphalan， prednisone， and thalidomide vs melphalan， prednisone， and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood， 2015， 126(11)： 1294-1301.
, 百拇医药
Srkalovic G， Cameron M， Rybicki L， et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer， 2004， 101(3)： 558-566.
Rajkumar S， Blood E， Vesole D， et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma： a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol.， 2006， 24(3)： 431-436.
, 百拇医药
Leleu X， Rodon P， Hulin C， et al. MELISSE， a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thromb. Haemost.， 2013， 110(4)： 844-851.
Carrier MLG， G.Tay， J.Wu， C.Lee， A. Y. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide： a systematic review and meta-analysis. J Thromb Haemost， 2011， 9(4)： 653-663.
, http://www.100md.com
Dede RJ， Pruemer JM. Comparing venous thromboembolism prophylactic strategies for ambulatory multiple myeloma patients on immunomodulatory drug therapy. Journal of Oncology Pharmacy Practice， 2016， 22(2)： 248-255.
Louzada MLM， M. V.Siqueira， L.Bermejo， J. M. B.Ocio， E. M.Porras， J. R. Comparing the efficacy of aspirin or low molecular weight heparin or vitamin k antagonists in the risk of thromboembolic events in patients with multiple myeloma treated with lenalidomide-based therapy. Blood， 2015， 126(23)： 1121.
, 百拇医药
Weber D， Chen C， Niesvizky R， et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med.， 2007， 357(21)： 2133-2142.
Rajkumar S， Jacobus S， Callander N， et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma： an open-label randomised controlled trial. Lancet Oncol.， 2010， 11(1)： 29-37., 百拇医药(晏建国 郭瑛 朱文凤 罗萍 胡飞 李金凤 欧阳贤凤)